Capsule Endoscopy after Hematopoietic Stem Cell Transplantation Can Predict Transplant-Related Mortality.


Journal

Digestion
ISSN: 1421-9867
Titre abrégé: Digestion
Pays: Switzerland
ID NLM: 0150472

Informations de publication

Date de publication:
2020
Historique:
received: 09 10 2018
accepted: 11 02 2019
pubmed: 25 3 2019
medline: 1 12 2020
entrez: 25 3 2019
Statut: ppublish

Résumé

Allogenic hematopoietic stem cell transplantation (allo-SCT) is a curative therapy for hematological malignancies, but transplant-related mortality (TRM) remains a concern. This study aimed to determine the efficacy of capsule endoscopy (CE) by evaluating the correlation between inflammatory findings on CE and TRM. The data of patients after allo-SCT were retrospectively collected. The association between findings on CE and TRM at 100 days from the CE was evaluated. Of the 94 patients included in the study, 47 showed inflammatory findings on CE. The findings were diagnosed as graft-versus-host disease (GVHD; n = 17), cytomegalovirus (CMV) infection (n = 14), and GVHD with CMV infection (n = 16). Of the 47 patients, 13 (28%) had TRM. Endoscopic diagnoses of these TRM cases were GVHD (n = 4), CMV infection (n = 0), and GVHD with CMV infection (n = 9). In contrast, in the remaining 47 patients who showed no inflammatory findings on CE, 2 patients (4%) had TRM. The proportion of TRM was higher in patients with inflammatory findings than in those without it (28 vs. 4%, p < 0.01). CE may predict TRM in patients who developed gastrointestinal symptoms after allo-SCT.

Sections du résumé

BACKGROUND AND OBJECTIVES OBJECTIVE
Allogenic hematopoietic stem cell transplantation (allo-SCT) is a curative therapy for hematological malignancies, but transplant-related mortality (TRM) remains a concern. This study aimed to determine the efficacy of capsule endoscopy (CE) by evaluating the correlation between inflammatory findings on CE and TRM.
METHODS METHODS
The data of patients after allo-SCT were retrospectively collected. The association between findings on CE and TRM at 100 days from the CE was evaluated.
RESULTS RESULTS
Of the 94 patients included in the study, 47 showed inflammatory findings on CE. The findings were diagnosed as graft-versus-host disease (GVHD; n = 17), cytomegalovirus (CMV) infection (n = 14), and GVHD with CMV infection (n = 16). Of the 47 patients, 13 (28%) had TRM. Endoscopic diagnoses of these TRM cases were GVHD (n = 4), CMV infection (n = 0), and GVHD with CMV infection (n = 9). In contrast, in the remaining 47 patients who showed no inflammatory findings on CE, 2 patients (4%) had TRM. The proportion of TRM was higher in patients with inflammatory findings than in those without it (28 vs. 4%, p < 0.01).
CONCLUSIONS CONCLUSIONS
CE may predict TRM in patients who developed gastrointestinal symptoms after allo-SCT.

Identifiants

pubmed: 30904916
pii: 000498846
doi: 10.1159/000498846
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

198-207

Informations de copyright

© 2019 S. Karger AG, Basel.

Auteurs

Kazuya Inoki (K)

Endoscopy Division, National Cancer Center Hospital, Tokyo, Japan, kinoki@med.showa-u.ac.jp.
Course of Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, Tokyo, Japan, kinoki@med.showa-u.ac.jp.

Yasuo Kakugawa (Y)

Endoscopy Division, National Cancer Center Hospital, Tokyo, Japan.
Cancer Screening Center, National Cancer Center Hospital, Tokyo, Japan.

Hiroyuki Takamaru (H)

Endoscopy Division, National Cancer Center Hospital, Tokyo, Japan.
Cancer Screening Center, National Cancer Center Hospital, Tokyo, Japan.

Masau Sekiguchi (M)

Endoscopy Division, National Cancer Center Hospital, Tokyo, Japan.
Cancer Screening Center, National Cancer Center Hospital, Tokyo, Japan.

Minori Matsumoto (M)

Endoscopy Division, National Cancer Center Hospital, Tokyo, Japan.
Cancer Screening Center, National Cancer Center Hospital, Tokyo, Japan.

Takahisa Matsuda (T)

Endoscopy Division, National Cancer Center Hospital, Tokyo, Japan.
Cancer Screening Center, National Cancer Center Hospital, Tokyo, Japan.

Ayumu Ito (A)

Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.

Takashi Tanaka (T)

Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.

Yoshihiro Inamoto (Y)

Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.

Shigeo Fuji (S)

Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.

Saiko Kurosawa (S)

Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.

Sung-Won Kim (SW)

Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.

Takahiro Fukuda (T)

Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.

Yuichiro Ohe (Y)

Course of Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, Tokyo, Japan.

Yutaka Saito (Y)

Endoscopy Division, National Cancer Center Hospital, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH